(News Bulletin 247) – Poxel announced on Thursday evening that it had drawn down the last two tranches of its equity financing line concluded with Iris Capital Investment.
This drawdown, for a total amount of two million euros, thus completes the equity financing line for an amount of six million euros which was signed this summer with the private equity firm Iris.
In a review of its activities, the biopharmaceutical company specializing in metabolic diseases also indicates that it is in discussions with a view to restructuring the debt agreement with IPF Partners (IPF) in order to finance its activities beyond December 2023.
Poxel explains that obtaining additional funding remains its main priority in order to be able to launch its proof-of-concept studies in adrenoleukodystrophy, a severe neurodegenerative disease.
In order to preserve its cash, the company has decided to implement a savings plan, including a reduction in its workforce.
As of September 30, its cash and cash equivalents amounted to €17.1 million
Copyright (c) 2022 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
